Cite
Disparity in survival benefits of pembrolizumab between Asian and non‐Asian patients with advanced cancers: A systematic review and meta‐regression analysis
MLA
Shang‐Hsuan Peng, et al. “Disparity in Survival Benefits of Pembrolizumab between Asian and Non‐Asian Patients with Advanced Cancers: A Systematic Review and Meta‐regression Analysis.” Cancer Medicine, vol. 12, no. 19, Oct. 2023, pp. 20035–51. EBSCOhost, https://doi.org/10.1002/cam4.6563.
APA
Shang‐Hsuan Peng, Ching‐Hung Lin, I‐Chun Chen, Ying‐Chun Shen, Dwan‐Ying Chang, Tom Wei‐Wu Chen, Shu‐Min Huang, Fu‐Chang Hu, & Yen‐Shen Lu. (2023). Disparity in survival benefits of pembrolizumab between Asian and non‐Asian patients with advanced cancers: A systematic review and meta‐regression analysis. Cancer Medicine, 12(19), 20035–20051. https://doi.org/10.1002/cam4.6563
Chicago
Shang‐Hsuan Peng, Ching‐Hung Lin, I‐Chun Chen, Ying‐Chun Shen, Dwan‐Ying Chang, Tom Wei‐Wu Chen, Shu‐Min Huang, Fu‐Chang Hu, and Yen‐Shen Lu. 2023. “Disparity in Survival Benefits of Pembrolizumab between Asian and Non‐Asian Patients with Advanced Cancers: A Systematic Review and Meta‐regression Analysis.” Cancer Medicine 12 (19): 20035–51. doi:10.1002/cam4.6563.